Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

121.32USD
12:37am IST
Change (% chg)

$0.02 (+0.02%)
Prev Close
$121.30
Open
$121.54
Day's High
$121.54
Day's Low
$120.80
Volume
1,235,538
Avg. Vol
2,529,346
52-wk High
$121.54
52-wk Low
$81.79

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $333,653.19
Shares Outstanding(Mil.): 2,750.64
Dividend: 0.80
Yield (%): 2.64

Financials

  JNJ.N Industry Sector
P/E (TTM): 22.11 35.75 36.59
EPS (TTM): 5.49 -- --
ROI: 14.06 14.84 14.10
ROE: 21.89 15.92 15.30

BRIEF-Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable

* Fitch affirms Johnson & Johnson's IDR at 'AAA'; outlook stable Source text for Eikon: Further company coverage:

30 Jun 2016

Fitch Affirms Johnson & Johnson's IDR at 'AAA'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, June 30 (Fitch) Fitch Ratings has affirmed Johnson & Johnson's (JNJ) Issuer Default Rating at 'AAA'. The Rating Outlook is Stable. A complete list of Fitch's rating actions follow at the end of this press release. KEY RATING DRIVERS The company's 'AAA' rating reflects the following: --Potential biosimilar competition for Remicade in the U.S. in late-2016/early-2017 and adverse foreign exchange movement will weigh on revenue

30 Jun 2016

BRIEF-Amyris announces collaboration with Johnson & Johnson Innovation

* Amyris announces collaboration with Johnson & Johnson innovation for biosynthetic drug discovery

06 Jun 2016

J&J myeloma drug, in combo regimen, delays worsening of the disease

Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.

05 Jun 2016

J&J myeloma drug, in combo regimen, delays worsening of the disease

June 5 Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.

05 Jun 2016

J&J to buy hair care products maker Vogue for $3.3 billion

Johnson & Johnson said on Thursday it would acquire Vogue International for $3.3 billion, adding brands such as OGX shampoos and FX hair styling products to its consumer portfolio that includes Neutrogena and Clean & Clear.

02 Jun 2016

UPDATE 2-J&J to buy hair care products maker Vogue for $3.3 bln

June 2 Johnson & Johnson said on Thursday it would acquire Vogue International for $3.3 billion, adding brands such as OGX shampoos and FX hair styling products to its consumer portfolio that includes Neutrogena and Clean & Clear.

02 Jun 2016

J&J to buy hair care products maker Vogue for $3.3 bln

June 2 Johnson & Johnson said on Thursday it would acquire Vogue International, a privately held hair care and personal care products maker, for about $3.3 billion in cash.

02 Jun 2016

BRIEF-Johnson & Johnson to acquire Vogue International for about $3.3 bln

* Johnson & Johnson announces agreement to acquire Vogue International

02 Jun 2016

BRIEF-European Commission approves Johnson & Johnson's TREVICTA

* Janssen-Cilag International NV says European Commission (EC) has approved use of TREVICTA for maintenance treatment of schizophrenia in adult patients Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

31 May 2016

Earnings vs. Estimates